Caladrius Biosciences, Rye Brook.
Translational Research Center for Medical Innovation (TRI), Foundation for Biomedical Research and Innovation at Kobe (FBRI).
Circ J. 2019 Jun 25;83(7):1422-1430. doi: 10.1253/circj.CJ-19-0240. Epub 2019 Jun 7.
In 1997, the seminal manuscript by Asahara, Murohara, Isner et al outlined the evidence for the existence of circulating, bone marrow-derived cells capable of stimulating and contributing to the formation of new blood vessels. Consistent with the paradigm shift that this work represented, it triggered much scientific debate and controversy, some of which persists 2 decades later. In contrast, the clinical application of autologous CD34 cell therapy has been marked by a track record of consistent safety and clinical benefit in multiple ischemic conditions. In this review, we summarize the preclinical and clinical evidence from over 700 patients in clinical trials of CD34 cell therapy.
1997 年，Asahara、Murohara、Isner 等人的开创性论文概述了循环骨髓来源细胞的存在证据，这些细胞能够刺激和促进新血管的形成。与这项工作所代表的范式转变一致，它引发了大量的科学争论和争议，其中一些争议在 20 年后仍在继续。相比之下，自体 CD34 细胞治疗的临床应用在多种缺血性疾病中具有一致的安全性和临床获益的记录。在这篇综述中，我们总结了超过 700 名患者的临床试验中的 CD34 细胞治疗的临床前和临床证据。
